No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Analysts at Berenberg upgraded drugmaker GSK from 'hold' to 'buy' on Tuesday and lifted their target price on the stock from £20 to £22, saying recent businessdevelopment activity and pipeline momentum had strengthened the firm's longterm growth outlook and left its valuation discount looking excessive.
Berenberg said GSK's evolution was "undervalued", noting that 10 of its 11 novel phaseIII assets had been sourced externally under new chief executive Luke Miels. It argued that six latestage programmes each carried potential peak sales of at least £2bn, helping to restock the pipeline and improve returns on R&D.
The German bank forecasts £39bn of sales in 2031, ahead of consensus and supported by recently launched products and underappreciated opportunities in bepirovirsen, Nuvalent's lungcancer assets and GSK/Hansoh ADCs. It added that margins should remain "stable to improving" despite future erosion in oral HIV brands, helped by ongoing costsaving measures.
Berenberg stated upcoming catalysts include US decisions on bepirovirsen and neladalkib by yearend, alongside key readouts over the next 12 months for RisRez in secondline SCLC, quarterly HIV dosing, and several midstage respiratory and allergy assets.
The broker added that GSK's valuation gap had become too wide, with the shares trading on 9.6x 2027 earnings versus 12.4x for European peers, and at a 22% discount on enterprise value-to-net present value ratio.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.